nav-left cat-right
cat-right

Trends in Drug Research 27th Noordwijkerhout-Camerino-Cyprus Conference Noordwijkerhout, The Netherlands, May 3 – 8, 2009

The Symposium is sponsored by the European Federation of Medicinal Chemistry (EFMC).

The Organising and Scientific Committees cordially invite you to attend the 27 edition of this meeting on Trends in Drug Research. The interplay between molecular structure and biological activity is central to contemporary biomedical and translational research, relevant not only to structural biologists but also to diverse scientists involved in the study of bioactive compounds and signalling mediators and those working in drug discovery and development.

The scientific programme will include plenary lectures, oral communications and poster sessions. Registration will open on Sunday May 3, followed by an inaugural evening lecture and a welcome gathering.
The scientific programme ends on Thursday May 7 and the meeting will be concluded by the symposium dinner on Thursday evening. On Friday after the conference, a complimentary workshop “Virtual Screening and De Novo Design” is offered by BioSolveIT.

REGISTRATION Information and the complete SCIENTIFIC PROGRAMME is available on the SYMPOSIUM’S WEBSITE: WWW.NOORDWIJKERHOUTMEDCHEM.ORG

PROGRAMME

Opening keynote lecture

Chairman Prof. Henk TIMMERMAN (VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Chemistry’s Role In Target Identification And Validation Dr. Scott A. BILLER (NOVARTIS, Cambridge, United States)

KINASE INHIBITORS: TARGETING THE NON-ATP SITE

Chairman: Dr. Edmond DIFFERDING (UCB, Braine-l’Alleud, Belgium)

Discovery And Development of Selective, Orally Bioavailable Tyrosine Kinase Inhibitors For Targeted Treatment Of Human Cancers Prof. Stephen K. BURLEY (SGX PHARMACEUTICALS, SAN DIEGO, United States)

Non-Competitive Inhibitors of MEK1: from Discovery to the Clinic Dr. Jeffrey OHREN (PFIZER, GROTON, United States)

Allosteric Inhibition of Kinase Function Philip E. SANDERSON (MERCK, Rahway, United States)

CHEMICAL AND ENZYMATIC MODIFICATION OF THERAPEUTIC PEPTIDES AND PROTEINS TO IMPROVE THEIR MODE OF ACTION

Chairman: Dr. Stan VAN BOECKEL (ORGANON, Oss, The Netherlands)

Title to be announced
Dr. Jesper LAU (NOVO NORDISK, Maaloev, Denmark)

Sugars and Proteins
Prof. Ben DAVIS (OXFORD UNIVERSITY, Oxford, United Kingdom)

CarboCarrier(TM): a Novel Technology to Extend the Half-life of Small Proteins and Peptides Martin DE KORT (ORGANON, Oss, The Netherlands)

PROMISES IN GPCR DRUG DISCOVERY

Chairman: Prof. ROB LEURS (LEIDEN/AMSTERDAM CENTER FOR DRUG RESEARCH, Amsterdam, The Netherlands)

Structural Genomics of GPCRs; New Opportunities for Drug Discovery Chris TATE (MRC LABORATORY OF MOLECULAR BIOLOGY, Cambridge , Belgium)

GPCR Hetero-Dimerisation: Contribution to Receptor Pharmacology and Function Prof. Graeme MILLIGAN (UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

Dicovery & Development of Allosteric Modulators: Hopes and Promises Dr Emmanuel LE POUL (ADDEX PHARMA, Plan les Ouates, Switzerland)

TRANSPORTERS

Chairman: Prof. Gerhard ECKER (UNIVERSITY OF VIENNA, Vienna, Austria)

Predicting Substrate Properties for ABC-Transporter – Safety Sciences on the Molecular Level Prof. Gerhard ECKER (UNIVERSITY OF VIENNA, Vienna, Austria)

Drug Transport and Metabolism: Value of Knockout and Transgenic Mouse Models Dr. Alfred SCHINKEL (HET NEDERLANDS KANKER INSTITUUT , Amsterdam, The Netherlands)

Title to be announced
Prof. Robert FORD (THE UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

OFF-TARGET EFFECTS

Chairman: Prof. Hugo KUBINYI (Weisenheim am Sand, Germany)

GPCR Antitargets – Prediction and Prevention of Side Effects Dr. Thomas KLABUNDE (SANOFI-AVENTIS DEUTSCHLAND GMBH, Frankfurt am Main, Germany)

Understanding Ion Channels Using Computational Approaches Dr. Marcel J. DE GROOT (PFIZER, Sandwich, United Kingdom)

The QSARome of the Receptorome: Development of Robust QSAR Models Capable of Predicting Compound Binding Profiles against Multiple Targets Prof. Alexander TROPSHA (UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, Chapel Hill, United States)

FRAGMENT BASED DRUG DISCOVERY

Chairman: Dr. Iwan DE ESCH (VRIJE UNIVERSITEIT AMSTERDAM, Amsterdam, The Netherlands)

Experiences in Fragment-based Lead Discovery Prof. Roderick E. HUBBARD (UNIVERSITY OF YORK, York, United Kingdom)

SPR Biosensor-Based Fragment Screening and Lead Characterization Prof. U. Helena DANIELSON (UPPSALA UNIVERSITY, Uppsala, Sweden)

Novel-Generation Kinase Inhibitors: Deep Pocket Binders by Fragment- Based Design Dr. Gerhard MÃœLLER (CSO PROTEROS FRAGMENTS GMBH, Munich/Martinsried, Germany)

ANTI-INFLAMMATORY DRUG DISCOVERY

Chairman: Robin THURMOND (JOHNSON & JOHNSON, San Diego, United States)

Histamine H4 Antagonists as Future Anti-Inflammatory Drugs Robin THURMOND (JOHNSON & JOHNSON, San Diego, United States)

JAK3 Kinase: a Molecular Target for Treatment of Inflammatory Diseases and Renal Transplant Rejection Dr. Paul S. CHANGELIAN (CHANGELIAN BIOSCIENCE, LLC, , United States)

Molecular Mechanim of Action for Chemokine and Other Anti-inflammatory Agents on 7TM Receptors Dr. Thue W. SCHWARTZ (UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

Complimentary Workshop on Friday: “Virtual Screening and De Novo Design” offered by BioSolveIT Late Departure – the transportation will be provided by the organisers.

http://www.LDOrganisation.com